BriaCell Therapeutics Corp.
BCT.TO
TSX
| 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -32.06% | 2.61% | -8.43% | -377.86% | -170.77% |
| Total Depreciation and Amortization | 0.00% | 0.00% | 0.00% | -63.12% | 1,805.26% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -3,561.31% | 102.61% | -156.64% | 122.16% | 60.27% |
| Change in Net Operating Assets | 137.76% | -223.69% | 141.28% | -262.87% | -65.37% |
| Cash from Operations | -13.54% | -20.99% | 14.88% | -72.34% | 20.62% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -6,939.05% | -40.00% | 0.00% | -- | 100.00% |
| Cash from Investing | -6,939.05% | -40.00% | 0.00% | 83.58% | -103.02% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -7.87% | 182.07% | -56.38% | 170.66% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -7.87% | 182.07% | -56.38% | 170.66% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -126.41% | 1,056.41% | -115.79% | 6,798.64% | 98.61% |